Dr. Hans-Josef Ritzert to Head Evonik's Chinese Business
Evonik has appointed Dr. Hans-Josef Ritzert as its regional president of greater China, effective Sept. 1. Ritzert currently heads the company's Exclusive Synthesis & Pharma Amino Acids business and was previously head of its Catalysts business. Evonik has about 3500 employees in the greater China region and had a turnover exceeding €1 billion in 2010. Ritzert, who holds a doctorate in chemistry, takes over the position from Dr. Dahai Yu, who was appointed to Evonik's executive board in April.
Dr. Jean-Luc Herbeaux will head the newly formed Health Care business line. Herbeaux, who has been leading the company's Pharma Polymers business since the beginning of 2009, joined Evonik Industries (then Degussa) in 2000.
most read
Novo Nordisk to Cut 9,000 Jobs Globally in Major Restructuring
Novo Nordisk announced a global workforce reduction of approximately 9,000 positions to streamline operations and reinvest DKK 8 billion (€1 billion) in growth opportunities for diabetes and obesity treatments.
BASF Sells Majority Stake in Coatings Business
BASF sells a majority stake in its coatings business to the investor Carlyle.
Merck Acquires Chromatography Business from JSR Life Sciences
Merck to acquire the chromatography business of JSR Life Sciences, a leading provider of CDMO services, preclinical and translational clinical research, and bioprocessing solutions.
Dow to Shut Down Three Upstream European Assets
Building on the April 2025 announcement, Dow will take actions across its three operating segments to support European profitability, resulting in the closure of sites in Germany and the UK.